---
title: "Centurion Corporation Limited (OU8) Receives a Buy from UOB Kay Hian"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283539048.md"
description: "UOB Kay Hian analyst Adrian Loh has maintained a Buy rating on Centurion Corporation Limited (OU8), setting a price target of S$1.90. The overall analyst consensus for the company is a Strong Buy, with an average price target of S$1.71. Loh is ranked #964 out of 12,162 analysts according to TipRanks."
datetime: "2026-04-21T17:05:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283539048.md)
  - [en](https://longbridge.com/en/news/283539048.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283539048.md)
---

# Centurion Corporation Limited (OU8) Receives a Buy from UOB Kay Hian

In a report released today, Adrian Loh from UOB Kay Hian maintained a Buy rating on Centurion Corporation Limited, with a price target of S$1.90.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Loh is ranked #964 out of 12162 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Centurion Corporation Limited with a S$1.71 average price target.

### Related Stocks

- [OU8.SG](https://longbridge.com/en/quote/OU8.SG.md)
- [U10.SG](https://longbridge.com/en/quote/U10.SG.md)

## Related News & Research

- [Lim & Tan Securities Reaffirms Their Buy Rating on Centurion Corporation Limited (OU8)](https://longbridge.com/en/news/272871667.md)
- [CGS International Sticks to Its Buy Rating for Centurion Corporation Limited (OU8)](https://longbridge.com/en/news/285000218.md)
- [Earnings Beat: Deepak Nitrite Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models](https://longbridge.com/en/news/286980047.md)
- [Why This Analyst Thinks Texas Instruments Stock Is on the Path to $1 Trillion](https://longbridge.com/en/news/286957345.md)
- [LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286679129.md)